IVD of Artemisia vulgaris Allergy
Artemisia vulgaris
Hay fever is a type of disease caused by patients being allergic to plant pollen, among which Artemisia pollen has the highest positive rate. Artemisia vulgaris pollen crude extract and one of its main components, Artemisia vulgaris 1 (Art V 1), can induce the occurrence of pollen allergy. Allergy patients mainly present with symptoms of allergic rhinitis and allergic conjunctivitis. Currently, in vitro diagnostics (IVD) methods for Artemisia vulgaris pollen allergy are usually implemented by detecting specific IgE antibodies in the patient's serum.
Main Steps of IVD for Artemisia vulgaris Allergy
- Skin prick test. The pollen allergy can be diagnosed using this method, which is simple, safe, and highly sensitive.
- The main immunological detection technologies include ImmunoCAP, Western blotting, and ELISA. Allergy can be diagnosed by detecting specific IgE antibodies in the patient's serum.
Creative BioMart provides high-quality recombinant Artemisia vulgaris allergen proteins used for IVD, including ELISA, lateral flow assays, western blots, and other immunoassays.
Highlights of Our Products
- High purity, no non-specific allergen contamination.
- High specificity. The molecular structure and biological activity of recombinant allergens are similar to natural allergens and can effectively stimulate immune responses in allergic patients.
- Easy to scale up production. A large number of specific proteins can be obtained through process amplification, without being limited by the content of natural extracts and materials.
- Higher safety and repeatability.
Our Outstanding Advantages
- Strong technical team, advanced scientific research equipment, and technology that can provide high-quality services.
- A rich variety of IVD products to meet the different needs of customers and provide customers with comprehensive scientific research support.
- Maintain exceptional service standards with precise and prompt provision of IVD-related services, ensuring an outstanding scientific research experience for our clients.
- We lead the IVD industry in developing IVD proteins with superior affinity, specificity, and immunogenicity, tailored to the needs of our customers.
Clinical Related Information
Symptoms
- Sneezing
- Runny or stuffy nose (allergic rhinitis)
- Itchy, red, or watery eyes (allergic conjunctivitis)
- Coughing
- Wheezing or difficulty breathing (asthma)
- Skin rashes or hives (in cases of contact dermatitis)
How to Overcome Artemisia vulgaris Allergy
Avoidance: The best way to manage an allergy is to avoid exposure to the allergen. This may include:
- Staying indoors during peak pollen seasons for mugwort (usually late summer to early autumn).
- Keeping windows closed to prevent pollen from entering the home.
- Using air purifiers with HEPA filters to reduce indoor pollen levels.
- Avoiding foods that cross-react with mugwort pollen, such as certain fruits, vegetables, and spices (this is known as Oral Allergy Syndrome).
Medications: Several medications can help alleviate the symptoms of mugwort allergies:
- Antihistamines: To reduce sneezing, itching, and runny nose.
- Nasal corticosteroids: To reduce inflammation in the nasal passages.
- Decongestants: To relieve nasal congestion.
- Leukotriene modifiers: To reduce symptoms related to asthma.
Immunotherapy (Allergy Shots): For long-term relief, immunotherapy can be effective. This treatment gradually desensitizes the immune system to the allergen over time via a series of injections.
Natural Remedies: Some people find relief through natural remedies such as:
- Saline nasal rinses: To clear pollen from nasal passages.
- Butterbur: An herbal supplement that some studies suggest might reduce allergy symptoms.
Consulting a Healthcare Professional: For severe or persistent symptoms, it is always best to consult an allergist or a healthcare professional for personalized treatment and management plans.
Case Study
Case 1: Zhang Q, Xi G, Yin J. Artemisia sieversiana pollen allergy and immunotherapy in mice. Am J Transl Res. 2021 Dec 15;13(12):13654-13664. PMID: 35035704; PMCID: PMC8748105.
This study developed a murine model of asthma using Artemisia sieversiana pollen extract (ASE) and subcutaneous immunotherapy (SCIT) without an adjuvant.
Fig2. Lung tissue eosinophilia and mucus production (20×). Lung specimens were stained with hematoxylin and eosin (H&E) and Alcian Blue periodic acid-Schiff (AB-PAS). Data represent the mean ± SD (n=10 mice/group). **P<0.01, asthma vs. control group.Case 2: Babayeva M, Tabynov K, Nurpeisov T, Fomin G, Renukaradhya GJ, Petrovsky N, Tabynov K. A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice. Front Immunol. 2022 Nov 9;13:983621. doi: 10.3389/fimmu.2022.983621. PMID: 36439113; PMCID: PMC9682083.
The aim of the present study was to evaluate a vaccine based on recombinant Artemisia vulgaris pollen major Art v 1 protein formulated with ISA-51 adjuvant for therapy of allergic rhinitis and bronchial asthma in Artemisia-sensitized mice in an ultrashort (4 subcutaneous injections at weekly intervals) pre- and co-seasonal ASIT regimen.
Fig3. Therapy for Artemisia vulgaris-induced allergic rhinitis and bronchial asthma in pre- and co-seasonal ASIT regimen with different vaccine formulations. Allergic rhinitis in mice after challenge with Artemisia vulgaris pollen was evaluated by the intensity of such clinical signs as sneezing, nasal rubbing, and their combination (A), and the number of Goblet cells in nasal mucosal epithelium by histological analysis (B).Case 3: Yin Z, Ouyang Y, Dang B, Zhang L. Pollen grading prediction scale for patients with Artemisia pollen allergy in China: A 3-day moving predictive model. Clin Transl Allergy. 2023 Jul;13(7):e12280. doi: 10.1002/clt2.12280. PMID: 37488741; PMCID: PMC10332133.
To develop a model of Artemisia pollen grading to predict development in patients with pollen allergy. Artemisia pollen data from four pollen monitoring stations in Beijing as well as the number of Artemisia pollen allergen serum specific immunoglobulin E positive cases in Beijing Tongren Hospital from 2014 to 2016 were used to develop a statistical model of pollen deposition and provide optimised threshold values.
Fig4. The association between the number of patients with Artemisia allergy and the 3‐day average pollen deposition.